68Ga-dOTA-NOC PET and peptide receptor radionuclide therapy in management of bilateral ovarian metastases from gastrointestinal carcinoid

3Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The management of neuroendocrine tumours is challenging when curative surgery is ruled out because of distant metastases. We report a case of gastrointestinal carcinoid with bilateral ovarian metastases in a 50-year-old female who received octreotide therapy followed by peptide receptor radionuclide therapy and surgery thereafter. Somatostatin receptor expression on neuroendocrine tumours has implications in diagnosis and therapy. 68Ga-DOTA-NOC PET is a recent advancement in the field of somatostatin receptor imaging. The lesions which demonstrate tracer uptake on positron emission tomographic studies can be further planned for treatment with octreotide and 177Lu-DOTA-TATE. The case in discussion responded well to non-invasive treatment options before proceeding to definitive surgical management. © The Author 2012. Published by Oxford University Press. All rights reserved.

Cite

CITATION STYLE

APA

Singla, S., Gupta, S., Reddy, R. M., Durgapal, P., & Bal, C. S. (2012). 68Ga-dOTA-NOC PET and peptide receptor radionuclide therapy in management of bilateral ovarian metastases from gastrointestinal carcinoid. Japanese Journal of Clinical Oncology, 42(12), 1202–1206. https://doi.org/10.1093/jjco/hys172

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free